{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:03:39Z","timestamp":1791565419380,"version":"4.3.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1007\/s11914-010-0027-y","type":"journal-article","created":{"date-parts":[[2010,8,31]],"date-time":"2010-08-31T02:43:14Z","timestamp":1283222594000},"page":"178-184","source":"Crossref","is-referenced-by-count":160,"title":["Bone Loss in Diabetes: Use of Antidiabetic Thiazolidinediones and Secondary Osteoporosis"],"prefix":"10.1007","volume":"8","author":[{"given":"Beata","family":"Lecka-Czernik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,1]]},"reference":[{"key":"27_CR1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1503\/cmaj.1031414","volume":"172","author":"AY Cheng","year":"2005","unstructured":"Cheng AY, Fantus IG: Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 2005, 172:213\u2013226.","journal-title":"CMAJ"},{"key":"27_CR2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev.biochem.77.061307.091829","volume":"77","author":"P Tontonoz","year":"2008","unstructured":"Tontonoz P, Spiegelman BM: Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008, 77:289\u2013312.","journal-title":"Annu Rev Biochem"},{"key":"27_CR3","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11914-010-0016-1","volume":"8","author":"B Lecka-Czernik","year":"2010","unstructured":"Lecka-Czernik B: PPARs in bone: the role in bone cell differentiation and regulation of energy metabolism. Curr Osteoporos Rep 2010, 8:84\u201390.","journal-title":"Curr Osteoporos Rep"},{"key":"27_CR4","first-page":"1085","volume":"10","author":"B Lecka-Czernik","year":"2009","unstructured":"\u2022 Lecka-Czernik B: Bone as a target of type 2 diabetes treatment. Curr Opin Investig Drugs 2009, 10:1085\u20131090. This article reviews the effect of T2DM and different antidiabetic therapies on the human skeleton.","journal-title":"Curr Opin Investig Drugs"},{"key":"27_CR5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/aje\/kwm106","volume":"166","author":"M Janghorbani","year":"2007","unstructured":"Janghorbani M, Van Dam RM, Willett WC, Hu FB: Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007, 166:495\u2013505.","journal-title":"Am J Epidemiol"},{"key":"27_CR6","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1359\/jbmr.081207","volume":"24","author":"M Yamamoto","year":"2009","unstructured":"Yamamoto M, Yamaguchi T, Yamauchi M, et al.: Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res 2009, 24:702\u2013709.","journal-title":"J Bone Miner Res"},{"key":"27_CR7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00223-008-9195-5","volume":"84","author":"P Vestergaard","year":"2009","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L: Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int 2009, 84:45\u201355.","journal-title":"Calcif Tissue Int"},{"key":"27_CR8","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.2337\/diacare.25.10.1749","volume":"25","author":"AV Schwartz","year":"2002","unstructured":"Schwartz AV, Hillier TA, Sellmeyer DE, et al.: Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care 2002, 25:1749\u20131754.","journal-title":"Diabetes Care"},{"key":"27_CR9","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1359\/jbmr.080323","volume":"23","author":"LJ Melton","year":"2008","unstructured":"Melton LJ, Leibson CL, Achenbach SJ, et al.: Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res 2008, 23:1334\u20131342.","journal-title":"J Bone Miner Res"},{"key":"27_CR10","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2337\/diab.44.7.775","volume":"44","author":"JC Krakauer","year":"1995","unstructured":"Krakauer JC, McKenna MJ, Buderer NF, et al.: Bone loss and bone turnover in diabetes. Diabetes 1995, 44:775\u2013782.","journal-title":"Diabetes"},{"key":"27_CR11","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.bone.2009.12.020","volume":"46","author":"S Huang","year":"2010","unstructured":"Huang S, Kaw M, Harris MT, et al.: Decreased osteoclastogenesis and high bone mass in mice with impaired insulin clearance due to liver-specific inactivation to CEACAM1. Bone 2010, 46:1138\u20131145.","journal-title":"Bone"},{"key":"27_CR12","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1210\/jc.2007-1270","volume":"93","author":"M Yamamoto","year":"2008","unstructured":"Yamamoto M, Yamaguchi T, Yamauchi M, et al.: Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2008, 93:1013\u20131019.","journal-title":"J Clin Endocrinol Metab"},{"key":"27_CR13","first-page":"316","volume":"5","author":"D Vashishth","year":"2005","unstructured":"Vashishth D: Collagen glycation and its role in fracture properties of bone. J Musculoskelet Neuronal Interact 2005, 5:316.","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"27_CR14","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1210\/jc.2008-2498","volume":"94","author":"AV Schwartz","year":"2009","unstructured":"\u2022 Schwartz AV, Garnero P, Hillier TA, et al.: Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 2009, 94:2380\u20132386. This study shows association between levels of circulating AGEs and increased fracture risk in T2DM patients.","journal-title":"J Clin Endocrinol Metab"},{"key":"27_CR15","doi-asserted-by":"crossref","first-page":"520465","DOI":"10.1155\/2008\/520465","volume":"2008","author":"MA Deeg","year":"2008","unstructured":"Deeg MA, Tan MH: Pioglitazone versus rosiglitazone: effects on lipids, lipoproteins, and apolipoproteins in head-to-head randomized clinical studies. PPAR Res 2008, 2008:520465.","journal-title":"PPAR Res"},{"key":"27_CR16","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","volume":"355","author":"SE Kahn","year":"2006","unstructured":"Kahn SE, Haffner SM, Heise MA, et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427\u20132443.","journal-title":"N Engl J Med"},{"key":"27_CR17","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457\u20132471.","journal-title":"N Engl J Med"},{"key":"27_CR18","first-page":"614","volume":"16","author":"M Wadman","year":"2010","unstructured":"Wadman M: Avandia outcome may signal change in epidemiologists\u2019 sway. Nat Med 2010, 16:614.","journal-title":"Nat Med"},{"key":"27_CR19","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","volume":"298","author":"AM Lincoff","year":"2007","unstructured":"Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298:1180\u20131188.","journal-title":"JAMA"},{"key":"27_CR20","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","volume":"351","author":"H Yki-Jarvinen","year":"2004","unstructured":"Yki-Jarvinen H: Thiazolidinediones. N Engl J Med 2004, 351:1106\u20131118.","journal-title":"Thiazolidinediones. N Engl J Med"},{"key":"27_CR21","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1210\/jc.2005-2226","volume":"91","author":"AV Schwartz","year":"2006","unstructured":"Schwartz AV, Sellmeyer DE, Vittinghoff E, et al.: Thiazolidinedione (TZD) use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006, 91:3349\u20133354.","journal-title":"J Clin Endocrinol Metab"},{"key":"27_CR22","doi-asserted-by":"crossref","unstructured":"Kanazawa I, Yamaguchi T, Yano S, et al.: Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus. Osteoporos Int 2010 Feb 4 [Epub ahead of print].","DOI":"10.1007\/s00198-009-1161-1"},{"key":"27_CR23","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1210\/jc.2007-2249","volume":"93","author":"D Glintborg","year":"2008","unstructured":"Glintborg D, Andersen M, Hagen C, et al.: Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 2008, 93:1696\u20131701.","journal-title":"J Clin Endocrinol Metab"},{"key":"27_CR24","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1210\/jc.2006-2646","volume":"92","author":"A Grey","year":"2007","unstructured":"Grey A, Bolland M, Gamble G, et al.: The peroxisome-proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007, 92:1305\u20131310.","journal-title":"J Clin Endocrinol Metab"},{"key":"27_CR25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00223-010-9352-5","volume":"86","author":"U Gruntmanis","year":"2010","unstructured":"Gruntmanis U, Fordan S, Ghayee HK, et al.: The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial. Calcif Tissue Int 2010, 86:343\u2013349.","journal-title":"Calcif Tissue Int"},{"key":"27_CR26","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2337\/dc07-2270","volume":"31","author":"SE Kahn","year":"2008","unstructured":"\u2022 Kahn SE, Zinman B, Lachin JM, et al.: Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008, 31:845\u2013851. This article provides a retrospective analysis of fracture risk and type of fractures among the ADOPT participants receiving rosiglitazone.","journal-title":"Diabetes Care"},{"key":"27_CR27","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1210\/jc.2009-0572","volume":"95","author":"B Zinman","year":"2010","unstructured":"Zinman B, Haffner SM, Herman WH, et al.: Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab 2010, 95:134\u2013142.","journal-title":"J Clin Endocrinol Metab"},{"key":"27_CR28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1503\/cmaj.080486","volume":"180","author":"YK Loke","year":"2009","unstructured":"\u2022 Loke YK, Singh S, Furberg CD: Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009, 180:32\u201339. This article provides a comprehensive review of available clinical trials in respect to the effect of TZDs on risk of fractures.","journal-title":"CMAJ"},{"key":"27_CR29","first-page":"491","volume":"15","author":"SG Jones","year":"2009","unstructured":"Jones SG, Momin SR, Good MW, et al.: Distal upper and lower limb fractures associated with thiazolidinedione use. Am J Manag Care 2009, 15:491\u2013496.","journal-title":"Am J Manag Care"},{"key":"27_CR30","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1210\/jc.2009-1385","volume":"95","author":"ZA Habib","year":"2010","unstructured":"Habib ZA, Havstad SL, Wells K, et al.: Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010, 95:592\u2013600.","journal-title":"J Clin Endocrinol Metab"},{"key":"27_CR31","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1001\/archinternmed.2009.214","volume":"169","author":"CR Dormuth","year":"2009","unstructured":"Dormuth CR, Carney G, Carleton B, et al.: Thiazolidinediones and fractures in men and women. Arch Intern Med 2009, 169:1395\u20131402.","journal-title":"Arch Intern Med"},{"key":"27_CR32","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/archinte.168.8.820","volume":"168","author":"C Meier","year":"2008","unstructured":"Meier C, Kraenzlin ME, Bodmer M, et al.: Use of thiazolidinediones and fracture risk. Arch Intern Med 2008, 168:820\u2013825.","journal-title":"Arch Intern Med"},{"key":"27_CR33","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1210\/jc.2008-2157","volume":"94","author":"DH Solomon","year":"2009","unstructured":"Solomon DH, Cadarette SM, Choudhry NK, et al.: A cohort study of thiazolidinediones and fractures in older adults with diabetes. J Clin Endocrinol Metab 2009, 94:2792\u20132798.","journal-title":"J Clin Endocrinol Metab"},{"key":"27_CR34","doi-asserted-by":"crossref","first-page":"e1000154","DOI":"10.1371\/journal.pmed.1000154","volume":"6","author":"IJ Douglas","year":"2009","unstructured":"Douglas IJ, Evans SJ, Pocock S, Smeeth L: The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med 2009, 6:e1000154.","journal-title":"PLoS Med"},{"key":"27_CR35","first-page":"87","volume":"48","author":"M Gradiser","year":"2007","unstructured":"Gradiser M, Matovinovic M, Vrkljan M: Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly. Croat Med J 2007, 48:87\u201391.","journal-title":"Croat Med J"},{"key":"27_CR36","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1359\/jbmr.091113","volume":"25","author":"D Gatti","year":"2010","unstructured":"Gatti D, Viapiana O, Rossini M, Silvano A: Rosiglitazone therapy is associated with major clinical improvements in a patient with fibrodysplasia ossificans progressive. J Bone Miner Res 2010, 25:1460\u20131462.","journal-title":"J Bone Miner Res"},{"key":"27_CR37","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1210\/en.2003-0746","volume":"145","author":"SO Rzonca","year":"2004","unstructured":"Rzonca SO, Suva LJ, Gaddy D, et al.: Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004, 145:401\u2013406.","journal-title":"Endocrinology"},{"key":"27_CR38","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1210\/en.2006-1587","volume":"148","author":"OP Lazarenko","year":"2007","unstructured":"Lazarenko OP, Rzonca SO, Hogue WR, et al.: Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 2007, 148:2669\u20132680.","journal-title":"Endocrinology"},{"key":"27_CR39","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00223-004-0224-8","volume":"75","author":"V Sottile","year":"2004","unstructured":"Sottile V, Seuwen K, Kneissel M: Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int 2004, 75:329\u2013337.","journal-title":"Calcif Tissue Int"},{"key":"27_CR40","unstructured":"Huang S, Syed F, Suva LJ, Lecka-Czernik B: Estrogen deficiency augments TZD-induced bone loss and fat accumulation in bone in vivo [abstract]. J Bone Miner Res 2009, 24(Suppl 1). Available at http:\/\/www.asbmr.org\/Meetings\/AnnualMeeting\/AbstractDetail.aspx?aid=2e0a4c8c-af53-41a8-8155-8818183333bc . Accessed August 2010."},{"key":"27_CR41","doi-asserted-by":"crossref","first-page":"18767","DOI":"10.1074\/jbc.M109.000836","volume":"284","author":"UI Modder","year":"2009","unstructured":"Modder UI, Monroe DG, Fraser DG, et al.: Skeletal consequences of deletion of steroid receptor coactivator-2\/transcription intermediary factor-2. J Biol Chem 2009, 284:18767\u201318777.","journal-title":"J Biol Chem"},{"key":"27_CR42","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/nm1672","volume":"13","author":"Y Wan","year":"2007","unstructured":"Wan Y, Chong LW, Evans RM: PPAR-gamma regulates osteoclastogenesis in mice. Nat Med 2007, 13:1496\u20131503.","journal-title":"Nat Med"},{"key":"27_CR43","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrg1122","volume":"4","author":"SL Teitelbaum","year":"2003","unstructured":"Teitelbaum SL, Ross FP: Genetic regulation of osteoclast development and function. Nat Rev Genet 2003, 4:638\u2013649.","journal-title":"Nat Rev Genet"},{"key":"27_CR44","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/jcb.21994","volume":"106","author":"KR Shockley","year":"2009","unstructured":"\u2022 Shockley KR, Lazarenko OP, Czernik PJ, et al.: PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem 2009, 106:232\u2013246. This article provides an extensive analysis of the effect of rosiglitazone on gene expression in marrow MSCs.","journal-title":"J Cell Biochem"},{"key":"27_CR45","doi-asserted-by":"crossref","first-page":"81219","DOI":"10.1155\/2007\/81219","volume":"2007","author":"KR Shockley","year":"2007","unstructured":"\u2022 Shockley KR, Rosen CJ, Churchill GA, Lecka-Czernik B: PPARgamma2 regulates a molecular signature of marrow mesenchymal stem cells. PPAR Res 2007, 2007:81219. This article demonstrates that PPAR-\u03b32 plays a major role in regulation of cell \"stemness.\"","journal-title":"PPAR Res"},{"key":"27_CR46","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1474-9728.2004.00127.x","volume":"3","author":"EJ Moerman","year":"2004","unstructured":"Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B: Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma\/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta\/BMP signaling pathways. Aging Cell 2004, 3:379\u2013389.","journal-title":"Aging Cell"},{"key":"27_CR47","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/ncprheum0070","volume":"2","author":"CJ Rosen","year":"2006","unstructured":"Rosen CJ, Bouxsein ML: Mechanism of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol 2006, 2:35\u201343.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"27_CR48","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1359\/JBMR.050503","volume":"20","author":"JJ Cao","year":"2005","unstructured":"Cao JJ, Wronski TJ, Iwaniec U, et al.: Aging increases stromal\/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. J Bone Miner Res 2005, 20:1659\u20131668.","journal-title":"J Bone Miner Res"},{"key":"27_CR49","doi-asserted-by":"crossref","first-page":"267S","DOI":"10.3945\/ajcn.2009.28449E","volume":"91","author":"LS Higgins","year":"2010","unstructured":"Higgins LS, Depaoli AM: Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. Am J Clin Nutr 2010, 91:267\u00a0S\u2013272\u00a0S.","journal-title":"Am J Clin Nutr"},{"key":"27_CR50","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nri2748","volume":"10","author":"CK Glass","year":"2010","unstructured":"Glass CK, Saijo K: Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol 2010, 10:365\u2013376.","journal-title":"Nat Rev Immunol"},{"key":"27_CR51","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1210\/endo.143.6.8834","volume":"143","author":"B Lecka-Czernik","year":"2002","unstructured":"Lecka-Czernik B, Moerman EJ, Grant DF, et al.: Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002, 143:2376\u20132384.","journal-title":"Endocrinology"},{"key":"27_CR52","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bone.2005.07.008","volume":"38","author":"OP Lazarenko","year":"2006","unstructured":"Lazarenko OP, Rzonca SO, Suva LJ, Lecka-Czernik B: Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone 2006, 38:74\u201385.","journal-title":"Bone"},{"key":"27_CR53","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2147\/VHRM.S936","volume":"3","author":"JM Stafford","year":"2007","unstructured":"Stafford JM, Elasy T: Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes. Vasc Health Risk Manag 2007, 3:503\u2013510.","journal-title":"Vasc Health Risk Manag"},{"key":"27_CR54","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/MED.0b013e3283344a05","volume":"17","author":"IP Wong","year":"2010","unstructured":"Wong IP, Baldock PA, Herzog H: Gastrointestinal peptides and bone health. Curr Opin Endocrinol Diabetes Obes 2010, 17:44\u201350.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"27_CR55","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","volume":"32","author":"B Zinman","year":"2009","unstructured":"Zinman B, Gerich J, Buse JB, et al.: Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009, 32:1224\u20131230.","journal-title":"Diabetes Care"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s11914-010-0027-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T07:42:16Z","timestamp":1740469336000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-010-0027-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,1]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["27"],"URL":"https:\/\/doi.org\/10.1007\/s11914-010-0027-y","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,1]]}}}